19 result(s) displayed (1 - 19 of 19):
Regarding biotech M&A, Credit Suisse Group AG (NYSE:CS) doesn't think there will be more megamergers in the next 12 to 18 months -- we could have told you that. CS did list, however, what it sees as smaller prime acquisition targets alongside possible suitors: Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by Abbott...
Posted on September 18, 2009 12:29 PM
In Bristol-Myers Squibb Co.'s (NYSE: BMS) bid to morph from a traditional drugmaker into a focused biopharma, the firm sold over-the-counter assets in Asia-Pacific (excluding China and Japan) to Taisho Pharmaceutical Co. Ltd. for $160 million. Bristol also sold its 97.8% stake in PT Bristol-Myers Squibb Indonesia Tbk to Taisho...
Posted on September 16, 2009 9:57 AM
Shares of late-stage oncology companies Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Seattle Genetics Inc. (NASDAQ:SGEN) are trading higher as the companies are seen as possible acquisition targets. They have similar specializations to Medarex Inc. (NASDAQ:MEDX), which is being acquired by Bristol-Myers Squibb Co. (NYSE:BMY) for $2.4 billion.A Reuters story on...
Posted on July 24, 2009 12:07 PM
Before releasing second-quarter earnings, cash-rich Bristol-Myers Squibb Co. (NYSE:BMY) said late Wednesday it's acquiring Medarex Inc. (NASDAQ: MEDX) for $2.4 billion, extending a string of recent deals in the oncology sector.Bristol chairman and CEO James Cornelius said in a statement, "Medarex's technology platform, people and pipeline provide a strong complement...
Posted on July 23, 2009 9:38 AM
Under CEO James Cornelius Bristol-Myers Squibb Co. (NYSE: BMS) has made major changes to its portfolio of businesses, en route to changing itself from a diversified healthcare company into a more tightly focused biopharma. We've noted many of the steps along the way, such as the February spinoff of Mead-Johnson...
Posted on May 5, 2009 9:44 AM
London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...
Posted on April 23, 2009 9:14 AM
While hopes of a Bristol-Myers Squibb Co. (NYSE:BMY) sale dwindle, the New York pharma giant is looking at other avenues to hedge against its blockbuster drugs facing generic competition. Bristol agreed with Japan's Otsuka Pharmaceutical Co. to extend a sales agreement for schizophrenia drug Abilify from November 2012 to April...
Posted on April 6, 2009 9:03 AM
Even before Pfizer Inc. (NYSE:PFE) announced its $68 billion acquisition of Wyeth in January, industry watchers had been expecting a wave of pharma deals. Like other observers, Tim Anderson of Bernstein Research thought Bristol-Myers Squibb Co. (NYSE:BMY) was a logical target, and he said so in June of 2008. But...
Posted on April 3, 2009 4:30 PM
Eli Lilly & Co. (NYSE:LLY) CEO John Lechleiter (pictured) wants to stop the mega-merger madness. He told the Financial Times the recent big drug mergers are "driven more by weakness" and are short-term fixes that fail to address long-term productivity problems. He specifically rejected the idea of a combo with...
Posted on March 30, 2009 2:04 PM
The trend of merging pharmas continued Monday with Merck & Co. (NYSE:MRK) and Schering-Plough Corp. (NYSE:SGP) announcing they would merge in a cash-and-stock deal worth $41.1 billion. The deal makes Merck the No. 2 drugmaker in the U.S. So what does that mean for competitors like Bristol-Myers Squibb Co. and...
Posted on March 9, 2009 9:27 AM
Big Pharmas are cutting costs; Bristol-Myers Squibb Co., Wyeth, Pfizer, Merck & Co., Schering-Plough Corp. and GlaxoSmithKline plc have all announced reductions in their U.S. sales forces. They're also worrying about life under the Democrats.Do they still want to replenish their pipelines with high-priced biotech drugs? James Greenwood, president and...
Posted on November 20, 2008 4:23 PM
Bristol-Myers Squibb Co. said its net earnings for the third quarter increased to about $2.6 billion from $858 million in the previous year's period. The New York-based pharma giant now has about $7.2 billion cash on hand, too. In a conference call, chairman and CEO James Cornelius said "we have a long list of companies, compounds, technologies we'd like to acquire over the next couple...
Posted on October 24, 2008 12:18 PM
Bristol-Myers Squibb Co. has initiated another step on its path from a diversified health and consumer products company to a focused biopharmaceutical firm. On Thursday morning Bristol-Myers chairman and CEO James Cornelius sent a letter to ImClone Systems Inc.'s chairman Carl Icahn about acquiring the company for $60 per...
Posted on July 31, 2008 8:56 AM
Less than a year after CEO John Mendlein steered his startup Adnexus Therapeutics into the arms of Bristol Myers Squibb Co. in a $430 million deal, Mendlein is hanging ten on the conference circuit. The tall, blond polymath - he has a physiology and biophysics PhD and a law...
Posted on June 19, 2008 8:23 AM
Drug developer Bristol-Myers Squibb Co. made another deal as it tries to focus on its pharmaceutical business, paying a 233% premium for cancer therapeutics company Kosan Biosciences. Bristol is paying $190 million cash hoping Kosan's late-stage drug Hsp90, among others, will come to market and bring in a few hundred...
Posted on May 30, 2008 7:56 AM
Ernst & Young has released a survey of 95 drug industry executives that shows heightened expectations for chief financial officers. As the industry grapples with slowing sales, tightening regulations, more aggressive generic competition, rapid globalization and a mountain of expiring patents, CFOs are expected to look beyond bean-counting and become...
Posted on March 28, 2008 9:01 AM
On March 31, Andrew Bonfield, executive vice president and chief financial officer of Bristol-Myers Squibb Co., will relinquish his role to Jean-Marc Huet. Huet (pictured) comes to BMS from the world of baby food. He was the engineer behind Amsterdam-based Royal Numico NV's acquisition strategy and their eventual $16.8 billion...
Posted on March 5, 2008 12:08 PM
Intel Capital's international march Intel Capital continues to strengthen its global reach with the appointment of Sudheer Kuppam as its new managing director for India, Japan, Australasia and southeast Asia. Kuppam formerly headed Intel Capital's flash memory and semiconductor investments. Now, he'll oversee the VC unit's $250 million fund...
Posted on June 15, 2007 10:05 AM
Licensing to commercial ventures is often the best chance that promising medical research has for survival outside the university or institutional lab.
Posted on December 15, 2006 8:42 PM
Movable Type search results powered by Fast Search
Juergen Lasowski
And the winners are...
